Clinical utility of the risperidone formulations in the management of schizophrenia

Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Madaan V, Bestha DP, Kolli VB, Jauhari S, Burket RC
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://doaj.org/article/4e22fb417ecc4272945dff6c78e223b5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:4e22fb417ecc4272945dff6c78e223b5
record_format dspace
spelling oai:doaj.org-article:4e22fb417ecc4272945dff6c78e223b52021-12-02T01:38:51ZClinical utility of the risperidone formulations in the management of schizophrenia1176-63281178-2021https://doaj.org/article/4e22fb417ecc4272945dff6c78e223b52011-10-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-the-risperidone-formulations-in-the-management-of--a8488https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use. Keywords: risperidone, schizophrenia, formulation, antipsychotic, side effectsMadaan VBestha DPKolli VBJauhari SBurket RCDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 611-620 (2011)
institution DOAJ
collection DOAJ
language EN
topic Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Madaan V
Bestha DP
Kolli VB
Jauhari S
Burket RC
Clinical utility of the risperidone formulations in the management of schizophrenia
description Vishal Madaan1, Durga P Bestha2, Venkata Kolli2, Saurabh Jauhari2, Roger C Burket1 1University of Virginia Health System, Charlottesville, VA, USA; 2Creighton University Medical Center, Omaha, NE, USA Abstract: Risperidone is one of the early second-generation antipsychotics that came into the limelight in the early 1990s. Both the oral and long-acting injectable formulations have been subject to numerous studies to assess their safety, efficacy, and tolerability. Risperidone is currently one of the most widely prescribed antipsychotic medications, used for both acute and long-term maintenance in schizophrenia. Risperidone has better efficacy in the treatment of psychotic symptoms than placebo and possibly many first-generation antipsychotics. Risperidone fares better than placebo and first-generation antipsychotics in the treatment of negative symptoms. Risperidone's long acting injectable preparation has been well tolerated and is often useful in patients with medication nonadherence. Risperidone has a higher risk of hyperprolactinemia comparable to first-generation antipsychotics (FGAs) but fares better than many second-generation antipsychotics with regards to metabolic side effects. In this article, we briefly review the recent literature exploring the role of risperidone formulations in schizophrenia, discuss clinical usage, and highlight the controversies and challenges associated with its use. Keywords: risperidone, schizophrenia, formulation, antipsychotic, side effects
format article
author Madaan V
Bestha DP
Kolli VB
Jauhari S
Burket RC
author_facet Madaan V
Bestha DP
Kolli VB
Jauhari S
Burket RC
author_sort Madaan V
title Clinical utility of the risperidone formulations in the management of schizophrenia
title_short Clinical utility of the risperidone formulations in the management of schizophrenia
title_full Clinical utility of the risperidone formulations in the management of schizophrenia
title_fullStr Clinical utility of the risperidone formulations in the management of schizophrenia
title_full_unstemmed Clinical utility of the risperidone formulations in the management of schizophrenia
title_sort clinical utility of the risperidone formulations in the management of schizophrenia
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/4e22fb417ecc4272945dff6c78e223b5
work_keys_str_mv AT madaanv clinicalutilityoftherisperidoneformulationsinthemanagementofschizophrenia
AT besthadp clinicalutilityoftherisperidoneformulationsinthemanagementofschizophrenia
AT kollivb clinicalutilityoftherisperidoneformulationsinthemanagementofschizophrenia
AT jauharis clinicalutilityoftherisperidoneformulationsinthemanagementofschizophrenia
AT burketrc clinicalutilityoftherisperidoneformulationsinthemanagementofschizophrenia
_version_ 1718402956544442368